Olokizumab
Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6) . Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis[1][2][3].
Product Specifications
CAS Number
1007223-17-7
Product Name Alternative
CDP 6038; OKZ
UNSPSC
12352203
Target
Interleukin Related; STAT
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Endocrinology; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/olokizumab.html
Purity
99.54
Solubility
10 mM in DMSO
Smiles
[Olokizumab]
Molecular Weight
(145.94 kDa)
References & Citations
[1]Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3 (6) :e119.|[2]Shaw S, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6 (3) :774-82.|[3]Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors & Clinical Investigation, 2016, 3.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-6; STAT3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
